IMPORTANCE Individuals with attention-deficit/hyperactivity disorder (ADHD) are at greater risk for academic problems. Pharmacologic treatment is effective in reducing the core symptoms of ADHD, but it is unclear whether it helps to improve academic outcomes.
A ttention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder among children and adolescents that can persist to adulthood. 1 It affects approximately 5% to 7% of the school-aged population [2] [3] [4] and slightly less than 3% of adults. [5] [6] [7] On average, individuals with ADHD earn lower school grades or standardized test scores and receive less schooling compared with peers without ADHD.
8-10
The core symptoms of ADHD, including inattention, impulsivity, and hyperactivity, may affect school performance; associated deficits, such as in attention span and working memory, may exacerbate academic difficulties.
11,12
Clinical trials have shown that ADHD medications are efficacious at reducing the core symptoms of ADHD 13 and are generally tolerated in children, adolescents, and adults, 5,14 although recent Cochrane systematic reviews graded this evidence as low quality. 15, 16 It is, however, less clear whether such improvement in behavior translates into better academic outcomes. Results from previous studies are mixed; more important, it is difficult to evaluate the educational significance of the measured outcomes.
17-20
Using information from the Swedish national registers, we examined the link between the use of ADHD medication and a nationally valued academic outcome in people who have received a diagnosis of ADHD. We chose a within-patient design, in which the same individual's test scores were examined when he or she was taking vs not taking medication. 
Methods

Patients
Measures Outcome
The outcome was the score on the Swedish Scholastic Aptitude Test (SweSAT; henceforth referred to as the test score). This is an optional standardized test 22 that has been an instrument, together with the grade point average from upper secondary schools in Sweden, for higher education selection in Sweden. Applicants to institutions of higher education are ranked by grade point average and/or the test score. There is no restriction on the number of times that one may retake the SweSAT; universities automatically consider an applicant's best test score. Therefore, it is common for applicants to take the test multiple times. The SweSAT is usually administered twice a year during April and October. Because the level of difficulty varied between tests, raw test scores were normed so that scores from different test occasions were comparable. 23 Since 2011, the test scores are normed to a scale between 0.00 and 2.00 (in increments of 0.05). We analyzed the normed test scores on its original scale multiplied by 100, yielding test scores ranging between 0 and 200. A total of 16 test occasions were included during the follow-up period. We extracted test records for the identified individuals with ADHD and excluded records of incomplete tests from the analyses. Age at testing was restricted to ages between 17 (because students start taking the tests during the second year of upper secondary school) and 30 years. For comparison, we extracted the test scores for population controls who were not diagnosed with ADHD and were matched with each case on sex, birth year, and residential area at the time of the first diagnosis at a ratio of 10:1.
Exposure
The exposure was ADHD medication. We extracted medication records of stimulants (including methylphenidate hydrochloride, amphetamine sulfate, and dextroamphetamine sulfate) and nonstimulants (atomoxetine hydrochloride) from the Prescribed Drug Register. In line with previous definitions, [24] [25] [26] we defined the medicated periods as having 2 dispensing records fewer than 6 months (183 days) apart. The nonmedicated periods are thus any period other than those defined as medicated periods during the follow-up. We assigned the test dates to the predefined medicated and nonmedicated periods to determine the medication status at the testing.
Covariates
In agreement with previous studies, 27,28 we observed significant linear and quadratic effects of age and practice (as measured by the number of previous tests taken) in association with the test scores, meaning that test scores improve at a declining rate as people get older and as they take more tests. This observation forms the basis of the adjustment in the main analyses using a within-patient design (the effects of covariates are shown in eTable 1 in the Supplement). Other covariates, including sex, test year, IQ (measured in stanine [standard nine] scores), and parents' highest educational level, were considered at the cohort level (the estimates are shown in eTable 2 in the Supplement).
Statistical Analysis
Data analysis was performed from November 24, 2015, to November 4, 2016. We first compared the basic characteristics between individuals with ADHD who had taken the Swe-SAT and their matched population controls, as well as between individuals with ADHD who took medication and did not take medication during the study follow-up period.
In the main analyses using the within-patient design, the eligible study participants were individuals with ADHD who had taken repeated tests and used ADHD medication during the follow-up period. We tested the association between medication use and the test scores using a conditional generalized estimating equation, with each patient as a separate cluster.
29,30
The analyses were performed with and without the adjustment of time-varying confounders, including age and the number of previous tests taken. Because each individual serves as his or her own control in this design, all the time-invariant confounders were implicitly adjusted for. We also tested the presence of carryover effects to ensure that the estimates were not biased (eAppendix in the Supplement).
For comparison, we also conducted analyses at the cohort level (ie, without controlling for confounding by indication). 31, 32 In these analyses, the test scores from all patients during medicated periods were compared with those during nonmedicated periods (referred to as "between-patient comparison"; in the eAppendix in the Supplement). All analyses were performed in R, version 3.2.3 (The R Project for Statistical Computing), using the R package drgee for the generalized estimating equation and conditional generalized estimating equation models. 33 P <.05 (2-sided) was considered significant.
Sensitivity Analyses
To investigate whether the results were sensitive to how the medicated and nonmedicated periods had been defined, we also assigned the medication status for each test date according to the number of days since the last dispensing. We reasoned that an individual is more likely to be taking medication if the test date is closer to the last dispensing, and conversely, less likely to be taking medication if there is a large gap in between the last dispensing and the test. The following cutoff values were tested: 6 months (183 days) to define both medicated and nonmedicated status, 3 months (91 days) to define both medicated and nonmedicated status, medicated status if the test date was no more than 3 months since the last dispensing, and unmedicated status if the last dispensing and the test date were more than 6 months apart (those with the gap between 3 and 6 months were set as missing). Stimulant ADHD medication might have different efficacy from nonstimulant medication. 34 To test whether different types of drugs might influence the test scores differently, we identified 2 groups: those who used only stimulants and those who used nonstimulants or a combination of medications. The association of medication use and the test scores was assessed within these 2 groups.
Attention-deficit/hyperactivity disorder frequently co-occurs with learning disabilities (LDs), but it has been shown that attention problems in patients with ADHD are not limited to its association with LDs. 35 points (95% CI, 9.73-16.53; P < .001) in the test scores. However, the effect was reduced to a 4.80-point increase (95% CI, 2.26-7.34; P < .001; Table 3 ) after accounting for age and practice effects. That is, among people who had taken multiple tests and used ADHD medications intermittently, the test scores were a mean of 4.80 points higher (on the scale of 0-200, or 0.048 on the original scale) when the patient was taking medication. The estimated improvement in the test scores appeared to be larger, although not significantly different, in males than in females (mean difference, 5.69; 95% CI, 2.14-9.23 for males vs 3.60; 95% CI, 0.06-7.14 for females; P =.31 for interaction of medication status and sex; Table 3 ).
In the between-patient comparison, we did not find a significant association between medication use and test scores (eTable 3 in the Supplement).
Within patients, medication was also linked with higher test scores when we used alternative definitions of medication status at the test date. The estimates of mean difference in the test scores, ranging between 3.56 (95% CI, 1.28-5.84) and 4.02 (95% CI, 1.34-6.69), were highly consistent even when we changed the number of days as different cutoff values (Table 4) .
Among the 930 individuals who took repeated tests and received ADHD medication, 665 (71.5%) used stimulants only. The association between stimulant medication and the test scores (difference, 3.81; 95% CI, 0.94-6.69) was weaker than the association with nonstimulant medications or a combination of medications (difference, 6.93; 95% CI, 1.81-12.05), although the estimates were not significantly different (P = .23 for interaction of medication status and type of users; Table 5 ). We identified fewer than 100 individuals with ADHD and coexisting LDs; this subset was too small to warrant separate analyses. Instead, we examined the association among individuals with ADHD who did not have comorbid LDs; the estimated mean test score difference was 5.05 points (95% CI, 2.47-7.62) in this subset.
In contrast, we found only a small, nonsignificant improvement in test scores associated with SSRI use regardless of adjustments for the use of ADHD medication. Within individuals with ADHD who had taken an SSRI, there was a 2.37-point difference (95% CI, -0.88 to 5.63; Table 5) in the mean test scores during periods when participants took SSRIs vs periods when they did not take SSRIs after adjusting for the use of ADHD medication.
Discussion
In this study, we examined the performance of individuals with ADHD on the higher education entrance examinations during medicated and nonmedicated periods. Among those with a diagnosis of ADHD, the use of ADHD medication was linked with higher scores in the SweSAT; this result survived several sensitivity analyses. The size of the effect was a 0.048-point improvement on the original scale of the test scores, equivalent to 0.11 SD. Comparing the magnitude of effects on test performance, the benefit from taking ADHD medication was comparable to having 1 previous test experience (0.12 SD). The effect might be stronger for individuals with average or high performance on the initial test (eAppendix and eTable 4 in the Supplement This effect size, albeit small, approximates to an increment of 0.05 in the normed test scores. Such improvement might translate to a higher rank among test applicants, potentially enhancing the chances of receiving higher education. The current results, therefore, might have an implication on an individual's educational attainment. In addition, educational level has been shown to be a strong indicator of occupational outcomes in adult patients with ADHD
43
; thus, the resultant better education might lead to other long-term implications. However, the small effect size suggested that other treatment programs are needed to help support individuals with ADHD in educational settings.
In the within-patient design, confounders that are constant within individuals (eg, genetic makeup for disease a In the within-patient comparison, the test scores during medicated periods were compared with nonmedicated periods in the same individual after adjusting for both linear and quadratic effects of age and the number of previous tests taken. The analyses were based on individuals with repeated tests.
b Total number of tests and the number of tests during the medicated vs nonmedicated periods are given in parentheses. All possible combinations of medication use were allowed.
c The significance of the interaction of medication status and sex was tested to indicate whether the mean test score differences during medicated vs nonmedicated periods were significantly different between males and females (P = .31). [OFF]) were from the within-patient analysis and adjusted for both linear and quadratic effects of age and the number of previous tests. The number of patients and tests were the same as presented in Table 3 (within-patient level). Abbreviations: ADHD, attention-deficit/hyperactivity disorder; LD, learning disability; SSRI, selective serotonin reuptake inhibitor; SweSAT, Swedish Scholastic Aptitude Test.
a Estimates of medication effect (ie, estimated mean difference in the test scores during medicated periods compared with nonmedicated periods) were from the within-patient analysis and adjusted for both linear and quadratic effects of age and the number of previous tests.
b The significance of the interaction of medication status and type of medication users was tested to indicate whether the mean test score differences during medicated vs nonmedicated periods were significantly different between patients only using stimulants and those using nonstimulants or a combination of medications (P = .23). 40 we inferred medication use during the test periods from medication prescription records. Thus, our results were not affected by any recall bias. The results, however, rely on whether the medication uses were correctly assigned. Using an alternative definition in which we traced the test date back to the closest drug dispensing and counted the number of days in between the 2 dates, we demonstrated that the observed association was not sensitive to the definition of medication exposure. However, there is still uncertainty about medication status on the test date. Previous studies have shown that nonadherence to an ADHD treatment regimen was the norm rather than the exception. 19 In the cases in which treatment nonadherence occurred during our defined medication periods, our estimation was likely to be conservative rather than an overestimate of the true medication effect.
Medication Use for ADHD and Performance on Higher Education Entrance Tests
Limitations
Because higher education entrance examinations comparable to the SweSAT exist in most countries, our results of a positive association between medication use and these tests in individuals with ADHD may be generalizeable to countries with a similar prevalence of ADHD medication use. There is a likelihood of some self-selection in our study. First, the proportion of individuals who had taken the SweSAT was nearly 3 times higher in the population controls than in the individuals with ADHD, probably owing to a higher percentage of school dropouts 45 
Conclusions
For the people with a diagnosis of ADHD, the use of ADHD medication is associated with better performance on higher education entrance tests. This evidence should be considered together with the current list of risks and benefits of ADHD medication to guide clinical decisions. Although the use of stimulants continues to increase in all age groups in the United States, 1 an important debate has emerged in the last 2 years about how effective stimulants are for treating attention-deficit/hyperactivity disorder (ADHD). For some investigators, the main message in the literature is clear: the quality of evidence from randomized clinical trials on the efficacy of stimulants is poor. 2 For others, the problem is in the meta-analysis from which these conclusions were taken.
3
This debate is highly focused on the efficacy of stimulants in core ADHD symptoms measured by scales. In working with patients, we have progressively understood that significant between-group differences in scores on ADHD scales are essential, but they are not sufficient. Patients and their families are interested in reallife outcomes; they want to know how medication affects grade retention, chances of car crashes, and unplanned adolescent pregnancies, among other outcomes. This situation is not a surprise because a previous systematic review showed that those affected by ADHD have significantly higher impairments in different areas of their lives than those without the disorder (eg, academic life, driving, drug use and addictive behavior, antisocial behavior, obesity, occupation, use of medical services, self-esteem, and social function outcomes). 4 The same review suggests that treatment might improve these outcomes but that residual effects remain since medicated patients did not function at the same level as those without ADHD. 4 In the same direction, a recent populationbased study with a sample of 766 244 students collected data on stimulant prescriptions and a variety of educational and health outcomes from 8 Scottish databases. 5 Youths receiving medication saw improvement in these outcomes, but they did not achieve the same level of functioning as those without the disorder. In this issue of JAMA Psychiatry,Luetal 6 add relevant data to this discussion. Their starting point was a clinically relevant research question: Can the use of ADHD medications improve performance on higher education entrance tests (a valued Swedish academic outcome) for individuals affected by the disorder? Using information from the Swedish National Registers, the authors selected 61 640 individuals with ADHD born between 1976 and 1996 who were followed up from January 1, 2006, to December 31, 2013. The exposure to ADHD medication was primarily defined as taking the entrance test in a period of less than 6 months between 2 records of dispensing ADHD medication. The authors also tested other definitions for exposure to medication. The outcome measure used was the score on the Swedish Scholastic Aptitude Test, an optional standardized test used in combination with grade point average for higher education selection in Sweden. Because individuals may take this test as often they like and universities consider the applicant's best test score, Lu et al 6 could implement an interesting strategy for their main data analyses: a within-patient design, in which the same individual's test scores were examined when he or she was taking and was not taking ADHD medication. The authors adjusted models for potential confounding effects of age and practice at taking the test. For secondary between-patient comparisons (cohortlevel analyses), the authors obtained test scores for population controls (at a ratio of 10:1) who did not receive a diagnosis of ADHD, matched with each case on sex, birth year, and residential area at the time of the first diagnosis. Finally, the authors also assessed the effect of selective serotonin reuptake inhibitors on the test scores for individuals with ADHD to ensure specificity for their findings.
The main results were (1) a significant positive effect of ADHD medication use on test scores in within-patient analyses, even after adjusting for the effects of age and practice at taking the test; (2) no effect for selective serotonin reuptake inhibitors on test scores, suggesting specificity for the effects of ADHD medication; and (3) no effect of ADHD medication on test scores in between-patient comparisons. These negative findings in the cohort-level analyses are not surprising because these analyses are more prone to effects of confounding variables.
Although these are encouraging findings with clear clinical effect, some caution is required. Although welldeveloped medical registers such as the Swedish National Registers have merits and methodological strengths, there are some methodological issues inherent to all large population samples. First, only a subgroup of individuals with ADHD was able to apply for university studies. A significant proportion of individuals with ADHD do not apply to college owing to ADHD's effect on academic achievement. 7 In addition, not all applicants took the entrance test in this study, and the Swedish Related article page 815
eAppendix. Methods
Testing carry-over effect:
The within-patient design assumes that there is no carry-over effect between exposures and outcomes for the same individual. 1 Carry-over effects, in this context, can take place in many forms, with some more plausible than others: for example, medication use at an earlier test can influence the decision of medication use ("exposure-to-exposure"), or more directly influence the scores ("exposure-to-outcome"), at the following test(s); or, an individual's scores at earlier tests can influence his or her scores ("outcome-tooutcome") or medication use ("outcome-to-exposure") at later test(s). Except for the first form (i.e., earlier medication use influence later use), these carry-over effects, if exist but are not accounted for, will lead to bias in the estimates from these models.
1 Therefore, we adjusted for the age and practice effects, both linear and quadratic terms, to account for the outcome-to-outcome carry-over. In addition, we tested the presence of the other two forms of carry-over, by fitting the specific paths into the model. To test whether the exposure-to-outcome carry-over exists, we examined the association of current test scores with the medication use at earlier tests, while adjusting for an indicator of the first test (because no information on the prior medication use), current medication use, as well as the age and practice effects. Similarly, to test whether the outcome-to-exposure carryover exist, we examined the association of current medication use with previous test scores, while adjusting for an indicator of first test, current test scores, as well as age and practice effects.
There was no evidence suggesting that the exposure-outcome carry-over effects exist. The effect of previous medication use on the current test score was not significantly different from 0 (-0.74 to 4.03), neither was the odds ratio of previous test score on the use of current medication different from 1 (0.99 to 1.03). These results suggest that the association between ADHD medication and test scores after controlling for the learning effect is not biased by other types of carry-over effects.
Between-patient comparison:
For comparison with results from the within-individual analysis, we also conducted analyses at the cohort level, i.e., the test scores from all patients during medicated periods were compared with those during non-medicated periods (referred to as 'between-patient comparison'); thus there was no restriction on study subjects. We used generalized estimation equation models to examine the associations between the use of ADHD medication and the test scores from all patients, with robust standard errors accounting for the correlated test scores from the same patients. The between-patient comparison was adjusted for age, sex, number of previous tests, test year, parental education level and IQ.
In the between-patient comparison when confounding by indication was not controlled for, we did not find a significant association between the medication use and the test score. For all individuals in the medicated ADHD group, the estimated mean difference in the test scores was 1.2 (95% CI, -2.4 to 4.8) comparing all medicated periods with nonmedicated periods (eTable 3).
Stratifying subjects by test performance:
In this sensitivity analysis, we aimed to test whether the association between ADHD medication and test scores differed among individuals with different test performance. We indirectly investigated this question by ranking subjects according to the scores from their first tests: those within the bottom 20% were considered as 'low' performance group, within top 20% were considered as 'high' performance group and the remaining ones were 'average' performance group. It should be noted that this represents a crude way of stratifying subjects, because scores at different test occasions which might have a varying level of difficulties were pooled together. We then performed within-individual analyses in each of these three groups. The results are shown in eTable 4.
There was no evidence for a medication effect among the low performance group. The medication effect appeared to be the strongest in the high performance group, but its wide confidence interval (CI) completely overlapped with the CI from the average performance group.
The concomitant use of SSRI:
The concomitant use of SSRI appeared to be more prevalent during ADHD medicated periods compared to non-medicated periods (eTable 5). We note that the non-significant improvement in test scores associated with SSRI, approximately 0.06 standard deviation of the test scores, was less likely to indicate a general effect related to medication pattern; instead, it was perhaps driven by the subset of individuals with ADHD and coexisting depression (within individuals with both ADHD and depression who had taken repeated tests, the estimated mean difference in the test scores due to SSRI was twice as large as the estimate from individuals with ADHD only, after adjusting for ADHD medication use; results not shown). This observation reflects previous findings that SSRI use is associated with improving attention and remaining executive function in patients with depression. 1.
In the between-patient comparison, the test scores from all individuals during medicated periods were compared with those during non-medicated periods, after adjusting for both linear and quadratic effects of age and the number of previous tests, test year, parents' highest education level (whether or not had over 12 years of education), and sex in the overall analysis. The presented results were not adjusted for IQ due to large percentage of missing data. 2.
Total number of tests and the number of tests during medicated versus nonmedicated periods in brackets. All possible combinations of medication use were allowed.
3.
The mean test score difference in the between-patient comparison was -1.02, 95% CI was -9.29 to 7.24 after adjusting for IQ.
